摘要【目的】探讨创面负压引流联合重组人生长激素治疗老年糖尿病足的疗效观察。【方法】选择老年糖尿病足患者102例,按照随机数表法分为观察组和对照组,每组51例。对照组采用创面负压引流术治疗,观察组在对照组基础上加用重组人生长激素治疗。比较两组疗效、创面愈合情况、住院时间、疼痛改善情况及治疗前后血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平。【结果】观察组治疗总有效率为94.12%,明显高于对照组的76.47%,其差异有统计学意义( P <0.05)。观察组肉芽组织生长厚度和创面愈合时间优于对照组( P <0.05)。观察组住院时间短于对照组,VAS评分低于对照组( P <0.05)。对照组治疗前后血清IGF-1和IGFBP-3水平无明显变化( P >0.05);观察组组治疗后血清IGF-1和IGFBP-3水平升高( P <0.05),且高于对照组( P <0.05)。【结论】创面负压引流联合重组人生长激素治疗老年糖尿病足患者疗效显著,促进创面愈合,提高血清IGF-1和IGFBP-3水平,值得临床推广应用。
Abstract：【Objective】 To investigate the effect of negative pressure and recombinant human growth hormone on senile diabetic foot. 【Methods】One hundred and two senile diabetic foot patients were randomly divided into observation group and control group with 51 cases in each group. The patients in the control group were treated with negative pressure drainage, and the patients in the observation group were treated with recombinant human growth hormone on the basis of the control group. The curative effect, wound healing, hospital stay, pain improvement and serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) were compared between the two groups before and after treatment. 【Results】 The total effective rate of treatment in the observation group was 94.12, which was significantly higher than that in the control group (76.47%), and the difference was statistically significant ( P < 0.05). The granulation tissue thickness and wound healing time in the observation group were better than those in the control group ( P < 0.05). The time of hospitalization in the observation group was shorter than that in the control group ( P < 0.05). The levels of serum IGF-1 and IGFBP-3 in the control group were not significantly changed before and after treatment ( P > 0.05), and the levels of serum IGF-1 and IGFBP-3 in the observation group increased after treatment ( P < 0.05) and were higher than those in the control group ( P < 0.05). 【Conclusion】 Negative pressure of wound combined with recombinant human growth hormone is effective in treating senile diabetic foot patients. It can promote wound healing and increase serum IGF-1 and IGFBP-3 levels, which is worthy of clinical application.
2018, Vol. 35 
